Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumor × atezolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 57 Carcinoma, Hepatocellular 45 Lung Neoplasms 27 Breast Neoplasms 26 Small Cell Lung Carcinoma 17 Neoplasms 17 Triple Negative Breast Neoplasms 16 Neoplasm Metastasis 16 Carcinoma, Transitional Cell 13 Melanoma 12 Colorectal Neoplasms 12 Urinary Bladder Neoplasms 11 Prostatic Neoplasms 9 Head and Neck Neoplasms 9 Recurrence 8 Ovarian Neoplasms 8 Liver Neoplasms 7 Glioblastoma 7 Mesothelioma, Malignant 6 Endometrial Neoplasms 6 Carcinoma, Renal Cell 6 Sarcoma 5 Rectal Neoplasms 5 Gastrointestinal Neoplasms 5 Carcinoma, Squamous Cell 5 Uterine Cervical Neoplasms 4 Stomach Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Pancreatic Neoplasms 4 Kidney Neoplasms 4

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡